Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations

Autism Clinical Trial

Official title:

Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02461446
• Other study ID #: P00013150
• Secondary ID: 1U54NS092090-01
• Status: Recruiting
• Start date: May 2015
• Est. completion date: December 2026

Study information

• Verified date: November 2023
• Source: Boston Children's Hospital
• Contact: Rajna Filip-Dhima, MS
• Phone: 617-919-7068
• Email: Rajna.Filip-Dhima[@]childrens.harvard.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In addition, this study will be creating and maintaining a biorepository and linked phenotypic database for PTEN ASD.

Description:

Autism spectrum disorders (ASD) are a set of neurodevelopmental disorders characterized by social communication/interaction impairments and restricted/repetitive behaviors. ASD associated with germline heterozygous PTEN mutations (PTEN ASD) is a genetically defined sub-group that, may be one of the more prevalent genetic disorders contributing to ASD (0.5-2%). The purpose of this research study is to carefully track the phenotypic and molecular characteristics of PTEN ASD and identify biomarkers for intervention studies.

Individuals with PTEN ASD, with macrocephalic ASD without a PTEN mutation (macro-ASD), healthy controls, and individuals with PTEN mutations without ASD (PTEN no-ASD) will be asked to participate in this study if they are 18 months and older. Both males and females will be asked to participate. Additionally, to be eligible for study participation, individuals' primary communicative language must be English.

The study involves 3 on site visits over the course of two years. Study visits will vary in length from about 4 hours to 6 hours. Study visits involve a physical exam, medical history questions, neuropsychological assessments, and a blood draw done for laboratory studies. A subset of participants between the ages of 2 and 11 years old will take part in the EEG portion of the study. Individuals who have a clinically indicated MRI will have an option to provide routine clinical scans for analysis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: December 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Months and older

Eligibility

Inclusion Criteria

• Individuals above the age of 18 months old at the time of consent who have documentation of a clinical diagnosis of autism spectrum disorder and/or a verified PTEN mutation from a medical or mental health professional for inclusion in the PTEN ASD, PTEN no-ASD or ASD macrocephaly groups.

• Macrocephaly (head circumference greater than or equal to 98th percentile) for inclusion in the ASD macrocephaly group.

• For youths, consent from parents or legal guardian. For adults, consent from self or legal guardian.

• Youths who are able (some young or severely impaired participants may not be able to provide assent) will be asked to provide assent as per IRB guidelines.

• Families with multiple children who meet the above inclusion criteria will be permitted to have as many children participate as they wish. A separate consent form will be filled out for each child enrolled in the study.

• Primary communicative language must be English

Exclusion Criteria

• Unwilling or unable to comply with study procedures and assessments

• Clinically significant medical disease that would prohibit participation in the study procedures.

• For subjects ELIGIBLE FOR OPTIONAL imaging biomarker assessment: contraindications to 3T MRI scanning, such as metal implants/non-compatible medical devices or medical conditions, including vagus nerve stimulator.

• For subjects ELIGIBLE FOR EEG/ERP biomarker assessment: contraindications to EEG/ERP, such as uncooperative or destructive behaviors preventing lead placement or capture by ERP/VEP equipment. Under age 2 or over 11 at the time of enrollment.

Related Conditions & MeSH terms

• ASD
• Autism
• Autistic Disorder
• Hamartoma Syndrome, Multiple
• Macrocephaly
• Neoplasms
• PTEN
• PTEN Hamartoma Tumor Syndrome

Locations

Country	Name	City	State
United States	Boston Children's Hospital	Boston	Massachusetts
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Cleveland Clinic	Cleveland	Ohio
United States	University of California at Los Angeles	Los Angeles	California
United States	Stanford University Medical Center	Stanford	California

Sponsors (6)

Lead Sponsor	Collaborator
Boston Children's Hospital	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Advancing Translational Sciences (NCATS), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Office of Rare Diseases (ORD)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in verbal abilities at 12 months	Verbal and non-verbal ability will be evaluated using Stanford Binet -5 or Mullen Scales of Early Learning (MSEL) at 12 months	12 months
Primary	Change in communication ability at 12 months	Communication ability will be evaluated using composite score of the Peabody Picture Vocabulary Test (PPVT-4).	12 months
Primary	Change in communication ability at 12 months	Communication ability will be evaluated using composite score of the Expressive Vocabulary Test (EVT-2) at 12 months.	12 months
Primary	Change in verbal abilities at 24 months	Verbal and non-verbal ability will be evaluated using Stanford Binet 5 or Mullen Scales of Early Learning (MSEL) at 24 months	24 months
Primary	Change in visual perception at 12 months	Visual perception will be measured using the Beery Developmental Test of Visuomotor Integration (VMI) at 12 months	12 months
Primary	Change in working memory at 12 months	Working memory will be evaluated using the Stanford Binet 5 at 12 months	12 months
Primary	Change in processing speed at 12 months	Processing Speed will be measured using the Processing Speed Index from the Weschler Intelligence Scales at 12 months	12 months
Primary	Change in working memory at 24 months	Working memory will be evaluated using the Stanford Binet 5 at 24 months	24 months
Primary	Change in processing speed at 24 months	Processing Speed will be measured using the Processing Speed Index from the Weschler Intelligence Scales at 24 months	24 months
Primary	Change in visual perception at 24 months	Visual perception will be measured using the Beery Developmental Test of Visuomotor Integration (VMI) at 24 months	24 months
Primary	Change in communication ability at 24 months	Communication ability will be evaluated using composite score of the Peabody Picture Vocabulary Test (PPVT-4) at 24 months	24 months
Primary	Change in communication ability at 24 months	Communication ability will be evaluated using composite score of the Expressive Vocabulary Test (EVT-2) at 24 months.	24 months